Serveur d'exploration Tocilizumab - Curation (PubMed)

Index « MedMesh.i » - entrée « Certolizumab Pegol »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Cerebrovascular Disorders < Certolizumab Pegol < Ceruletide  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 39.
[0-20] [0 - 20][0 - 39][20-38][20-40]
Ident.Authors (with country if any)Title
000416 (2019) Noemi Muszbek [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Marie Fournier [France] ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Zsofia Kiss [Royaume-Uni] ; Peter Gal [Hongrie] ; Kaleb Michaud [États-Unis]Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
000591 (2019) Carlo Salvarani [Italie] ; Gulen Hatemi [Turquie]Management of large-vessel vasculitis.
000655 (2018) Ettore Silvagni [Italie] ; Alessandra Bortoluzzi [Italie] ; Greta Carrara [Italie] ; Anna Zanetti [Italie] ; Marcello Govoni [Italie] ; Carlo Alberto Scirè [Italie]Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
000712 (2018) Pavel I. Novikov [Russie] ; Ilya O. Smitienko [Russie] ; Maria V. Sokolova [Russie] ; Fatma Alibaz-Oner [Turquie] ; Sema Kaymaz-Tahra [Turquie] ; Haner Direskeneli [Turquie] ; Sergey V. Moiseev [Russie]Certolizumab pegol in the treatment of Takayasu arteritis.
000805 (2018) Rahul Sehgal [États-Unis] ; Erik J. Stratman [États-Unis] ; Jonathan E. Cutlan [États-Unis]Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience.
000812 (2018) Andrew I. Rutherford [Royaume-Uni] ; Sujith Subesinghe [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni] ; James B. Galloway [Royaume-Uni]Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
000875 (????) Sergio Iannazzo [Italie] ; Maurizio Benucci [Italie] ; Ennio Giulio Favalli [Italie]Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
000892 (????) P Ivi H. Salonen [Finlande] ; Hanna S Il [Finlande] ; Juha H. Salonen [Finlande] ; Miika Linna [Finlande] ; Mika Helminen [Finlande] ; Markku J. Kauppi [Finlande]Pneumonia in children with juvenile idiopathic arthritis in Finland 1999-2014: a nationwide retrospective register linkage study.
000925 (2017) Sonja Dulic [Hongrie] ; Zs Fia Vásárhelyi [Hongrie] ; Florentina Sava [Hongrie] ; Lászl Berta [Hongrie] ; Balázs Szalay [Hongrie] ; Gergely Toldi [Hongrie] ; Lászl Kovács [Hongrie] ; Attila Balog [Hongrie]T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy.
000983 (2017) Benjamin Chastek [États-Unis] ; Chieh-I Chen [États-Unis] ; Clare Proudfoot [Royaume-Uni] ; Shraddha Shinde [États-Unis] ; Andreas Kuznik [États-Unis] ; Wenhui Wei [États-Unis]Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
000B24 (2017) I Igo Bermejo [Royaume-Uni] ; Matt Stevenson [Royaume-Uni] ; Rachel Archer [Royaume-Uni] ; John W. Stevens [Royaume-Uni] ; Edward Goka [Royaume-Uni] ; Mark Clowes [Royaume-Uni] ; David L. Scott [Royaume-Uni] ; Adam Young [Royaume-Uni]Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
000B79 (2018) Shingo Nakayamada [Japon] ; Satoshi Kubo [Japon] ; Maiko Yoshikawa [Japon] ; Yusuke Miyazaki [Japon] ; Naoki Yunoue [Japon] ; Shigeru Iwata [Japon] ; Ippei Miyagawa [Japon] ; Shintaro Hirata [Japon] ; Kazuhisa Nakano [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon]Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
000C01 (2017) Jeroen P. Jansen [États-Unis] ; Devin Incerti [États-Unis] ; Alex Mutebi [États-Unis] ; Desi Peneva [États-Unis] ; Joanna P. Macewan [États-Unis] ; Bradley Stolshek [États-Unis] ; Primal Kaur [États-Unis] ; Mahdi Gharaibeh [États-Unis] ; Vibeke Strand [États-Unis]Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
000C58 (2017) Simon Tarp [Danemark] ; Daniel Eric Furst [États-Unis] ; Maarten Boers ; George Luta [États-Unis] ; Henning Bliddal [Danemark] ; Ulrik Tarp ; Karsten Heller Asmussen [Danemark] ; Birgitte Brock ; Anna Dossing [Danemark] ; Tanja Schj Dt J Rgensen [Danemark] ; Steffen Thirstrup [Danemark] ; Robin Christensen [Danemark]Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
000C90 (2017) Aleksander Lenert [États-Unis] ; Petar Lenert [États-Unis]Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.
000D01 (2016) Jasvinder A. Singh ; Alomgir Hossain ; Elizabeth Tanjong Ghogomu ; Amy S. Mudano ; Peter Tugwell ; George A. WellsBiologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
000E08 (2016) Alberto Batticciotto [Italie] ; Roberto Ravasio [Italie] ; Marta Riva [Italie] ; Piercarlo Sarzi-Puttini [Italie]Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.
000E28 (2016) Nobunori Takahashi ; Naoki Ishiguro[Mechanism of action of biological disease--modifying antirheumatic drugs].
000E39 (2016) Celia Almeida ; Ernest H S. Choy ; Sarah Hewlett ; John R. Kirwan ; Fiona Cramp ; Trudie Chalder ; Jon Pollock ; Robin ChristensenBiologic interventions for fatigue in rheumatoid arthritis.
000E51 (????) Fabiola Atzeni ; Alberto Batticciotto ; Ignazio F. Masala ; Rossella Talotta ; Maurizio Benucci ; Piercarlo Sarzi-PuttiniInfections and Biological Therapy in Patients with Rheumatic Diseases.
000E60 (2016) Jasvinder A. Singh ; Alomgir Hossain ; Elizabeth Tanjong Ghogomu ; Ahmed Kotb ; Robin Christensen ; Amy S. Mudano ; Lara J. Maxwell ; Nipam P. Shah ; Peter Tugwell ; George A. WellsBiologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/MedMesh.i -k "Certolizumab Pegol" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/MedMesh.i  \
                -Sk "Certolizumab Pegol" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Curation
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Certolizumab Pegol
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021